The DOI matches its Crossref record; 24 of the 25 references it cites were found in a registry or an index.
Effect of gene therapy on visual function in Leber’s congenital amaurosis
Open accessAbstract
Early-onset, severe retinal dystrophy caused by mutations in the gene encoding retinal pigment epithelium-specific 65-kD protein (RPE65) is associated with poor vision at birth and complete loss of vision in early adulthood. We administered to three young adult patients subretinal injections of recombinant adeno-associated virus vector 2/2 expressing RPE65 complementary DNA (cDNA) under the control of a human RPE65 promoter. There were no serious adverse events. There was no clinically significant change in visual acuity or in peripheral visual fields on Goldmann perimetry in any of the three patients. We detected no change in retinal responses on electroretinography. One patient had significant improvement in visual function on microperimetry and on dark-adapted perimetry. This patient also showed improvement in a subjective test of visual mobility. These findings provide support for further clinical studies of this experimental approach in other patients with mutant RPE65. (ClinicalTrials.gov number, NCT00643747 [ClinicalTrials.gov].).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“during Phase I/II clinical trials for Leber's congenital amaurosis (LCA), over 30 patients who received a subretinal injection of AAV2 encoding RPE65, an enzyme responsible for the isomerohydrolase activity of retinal pigment epithelium, showed sustained improvement in both subjective and objective measurements of vision.8–14”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Adeno-associated virus has been successful in clinical gene therapy trials for Leber's congenital amaurosis, hemophilia, familial lipoprotein lipase deficiency, and choroideremia.8–15,26,27,60,61”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Despite a 28-day oral corticosteroid therapy started 2 days before the first IVT, a regimen similar to that provided in several other clinical studies using IVT or sub-retinal AAV-based gene therapies,41–45 70.7% of lenadogene nolparvovec-treated eyes developed some degree of intraocular inflammation versus 10.2% of placebo-treated eyes.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [41]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result, AAV clinical successes to date have involved delivery either to immune privileged regions or to subjects lacking apparent AAV immunological memory.8–14,30,42”
From Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates (2015) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“The techniques underpinning AAV-mediated retinal gene therapy have undergone iterative improvement since the first-in-human studies in RPE65 -associated IRDs (Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Bainbridge et al., 2008
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Dose finding studies have shown that a high number of rAAV particles (>10 12 viral genomes (vg)) can give rise to transient inflammation in mice [35].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [35]
Experimental — accuracy not yet measuredIn the citing paper
“Direct injection into the subretinal space, as was the route for the first FDA-approved AAV vector, results in less exposure to plasma proteins, circulating antibodies, blood cells, and tissue-resident phagocytic cells [15].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [15]
In the citing paper
“Gene therapy gained its place in mainstream medical practice following FDA approval of Luxturna, an AAV2- based treatment for the inherited retinal disease (IRD) retinal pigment epithelium (RPE)65-LCA (LCA2).”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [71]
In the citing paper
“In phase I/II clinical trials for RPE65-LCA at University College London (ClinicalTrials.gov: NCT00643747), ocular inflammation was noted following SRI of 1 × 1012 vg of AAV2-RPE65.71,99”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [71]
In the citing paper
“Treated patients exhibited life-changing improvements in light sensitivity and visually guided behavior.”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [71]
In the citing paper
“CNS-directed AAV delivery has been associated with an increase in inflammatory mediators, including neutralizing antibodies, circulating CD45+ leukocytes, natural killer cells, and CD8+ and CD4+ T cells.13,14,15,16,17,18,19”
From An innate immune response to adeno-associated virus genomes decreases cortical dendritic complexity and disrupts synaptic transmission (2024) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene therapy restores vision in a canine model of childhood blindness
Acland, G. M., Aguirre, G. D., Ray, J., Zhang, Q., Aleman, T. S., Cideciyan, A. V., Pearce-Kelling, S. E., Anand, V., Zeng, Y., Maguire, A. M., et al. (2001) · Nature Genetics · doi:10.1038/ng0501-92 · Cited by 1,202
Rpe65 is necessary for production of 11-cis-vitamin A in the retinal visual cycle
Redmond., T. M., Yu, S., Lee, E., Bok, D., Hamasaki, D., Chen, N., Goletz, P., Ma, J.-X., Crouch, R. K., & Pfeifer, K. (1998) · Nature Genetics · doi:10.1038/3813 · Cited by 929
Mutations in RPE65 cause autosomal recessive childhood–onset severe retinal dystrophy
Gu, S.-M., Thompson, D. A., Srikumari, C. R. S., Lorenz, B., Finckh, U., Nicoletti, A., Murthy, K. R., Rathmann, M., Kumaramanickavel, G., Denton, M. J., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-194 · Cited by 663
Mutations in RPE65 cause Leber's congenital amaurosis
Marlhens, F., Bareil, C., Griffoin, J.-M., Zrenner, E., Amalric, P., Eliaou, C., Liu, S.-Y., Harris, E., Redmond, T. M., Arnaud, B., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-139 · Cited by 606
RPE65 is the isomerohydrolase in the retinoid visual cycle
Moiseyev, G., Chen, Y., Takahashi, Y., Wu, B. X., & Ma, J.-X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503460102 · Cited by 536
Morimura, H., Fishman, G. A., Grover, S. A., Fulton, A. B., Berson, E. L., & Dryja, T. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3088 · Cited by 481
Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium
Jin, M., Li, S., Moghrabi, W. N., Sun, H., & Travis, G. H. (2005) · Cell · doi:10.1016/j.cell.2005.06.042 · Cited by 424
Redmond, T. M., Poliakov, E., Yu, S., Tsai, J.-Y., Lu, Z., & Gentleman, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504167102 · Cited by 409
Hanein, S., Perrault, I., Gerber, S., Tanguy, G., Barbet, F., Ducroq, D., Calvas, P., Dollfus, H., Hamel, C., Lopponen, T., et al. (2004) · Human Mutation · doi:10.1002/humu.20010 · Cited by 350
Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog
Narfstro¨m, K., Katz, M. L., Bragadottir, R., Seeliger, M., Boulanger, A., Redmond, T. M., Caro, L., Lai, C.-M., & Rakoczy, P. E. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0595 · Cited by 252
Research works printed but not linked: 4
- Lorenz B, 2000, Invest Ophthalmol Vis Sci, 41, 2735
- Thompson DA, 2000, Invest Ophthalmol Vis Sci, 41, 4293
- Znoiko SL, 2002, Invest Ophthalmol Vis Sci, 43, 1604
- 10.1038/88327 · DOI
Cited by
Sorted by citations
Items 601–700 of 1,016
Serotype survey of AAV gene delivery via subconjunctival injection in mice
Song, L., Llanga, T., Conatser, L. M., Zaric, V., Gilger, B. C., & Hirsch, M. L. (2018) · Gene Therapy · doi:10.1038/s41434-018-0035-6 · Cited by 50
Non-viral therapeutic approaches to ocular diseases: An overview and future directions
Zulliger, R., Conley, S. M., & Naash, M. I. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.007 · Cited by 50
A wise consistency: engineering biology for conformity, reliability, predictability
Arkin, A. P. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.09.012 · Cited by 50
Sharma, A., Ghosh, A., Hansen, E. T., Newman, J. M., & Mohan, R. R. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.005 · Cited by 50
The eye as a model of ageing in translational research – Molecular, epigenetic and clinical aspects
Pathai, S., Shiels, P. G., Lawn, S. D., Cook, C., & Gilbert, C. E. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.11.002 · Cited by 50
Gene Therapy of Inherited Retinopathies: A Long and Successful Road from Viral Vectors to Patients
Colella, P., & Auricchio, A. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.123 · Cited by 54
Ultrasound-targeted microbubble destruction in gene therapy: A new tool to cure human diseases
Wu, J., & Li, R. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.08.001 · Cited by 50
Simunovic, M. P., Xue, K., Jolly, J. K., & MacLaren, R. E. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.5630 · Cited by 50
Presentation of TRPM1-Associated Congenital Stationary Night Blindness in Children
Utz, V. M., Pfeifer, W. L., Longmuir, S. Q., Olson, R. J., Wang, K., & Drack, A. V. (2018) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.0185 · Cited by 51
Laradji, A. M., Kolesnikov, A. V., Karakoçak, B. B., Kefalov, V. J., & Ravi, N. (2021) · ACS Omega · doi:10.1021/acsomega.0c05535 · Cited by 50
The Genomic Response of the Retinal Pigment Epithelium to Light Damage and Retinal Detachment
Rattner, A., Toulabi, L., Williams, J., Yu, H. M., & Nathans, J. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.2401-08.2008 · Cited by 50
Convergence of Human Genetics and Animal Studies: Gene Therapy for X-Linked RetinoschisisPreprint
Bush, R. A., Wei, L. L., & Sieving, P. A. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a017368 · Cited by 52
Chandler, L., Yusuf, I., McClements, M., Barnard, A., MacLaren, R., & Xue, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144972 · Cited by 49
Cwerman-Thibault, H., Augustin, S., Ellouze, S., Sahel, J.-A., & Corral-Debrinski, M. (2014) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2013.11.011 · Cited by 49
Genome editing in the treatment of ocular diseases
Choi, E. H., Suh, S., Sears, A. E., Hołubowicz, R., KEDHAR, S. R., Browne, A., & Palczewski, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01057-2 · Cited by 51
Nanoplatform‐Based In Vivo Gene Delivery Systems for Cancer Therapy
Luo, R., Le, H., Wu, Q., & Gong, C. (2024) · Small · doi:10.1002/smll.202312153 · Cited by 50
Cloning humans? Biological, ethical, and social considerations
Ayala, F. J. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1501798112 · Cited by 51
Promising and delivering gene therapies for vision loss
Carvalho, L. S., & Vandenberghe, L. H. (2014) · Vision Research · doi:10.1016/j.visres.2014.07.013 · Cited by 51
Connelly, J. P., Barker, J. C., Pruett‐Miller, S. M., & Porteus, M. H. (2010) · Molecular Therapy · doi:10.1038/mt.2010.57 · Cited by 49
The gene therapy journey for hemophilia: are we there yet?
High, K. A. (2012) · PubMed · doi:10.1182/asheducation-2012.1.375 · Cited by 49
Personalized therapeutic strategies for patients with retinitis pigmentosa
Zheng, A., Li, Y., & Tsang, S. H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1006192 · Cited by 50
Treharne, A. J., Grossel, M. C., Lotery, A. J., & Thomson, H. A. (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.184002 · Cited by 51
Reid, C. A., Ertel, K. J., & Lipinski, D. M. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22281 · Cited by 49
Pathways and disease-causing alterations in visual chromophore production for vertebrate vision
Kiser, P. D., & Palczewski, K. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.014405 · Cited by 50
Yzer, S., den Hollander, A. I., López, I., Pott, J.-W. R., de Faber, J. T., Cremers, F. P. M., Koenekoop, R. K., & van den Born, L. I. (2012) · PubMed Central · Cited by 49
AAV‐mediated gene delivery in Dp71‐null mouse model with compromised barriers
Vacca, O., Darche, M., Schaffer, D. V., Flannery, J. G., Sahel, J., Rendon, A., & Dalkara, D. (2014) · Glia · doi:10.1002/glia.22617 · Cited by 48
Nicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
Temporal interactions during paired-electrode stimulation in two retinal prosthesis subjects
Horsager, A., Boynton, G. M., Greenberg, R. J., & Fine, I. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5282 · Cited by 48
Wang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 51
Advances in repairing the degenerate retina by rod photoreceptor transplantation
Pearson, R. A. (2014) · Biotechnology Advances · doi:10.1016/j.biotechadv.2014.01.001 · Cited by 51
Chuah, M., Evens, H., & VandenDriessche, T. (2013) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12215 · Cited by 49
Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells
Koirala, A., Makkia, R. S., Cooper, M. J., & Naash, M. I. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.08.062 · Cited by 49
Physiological and tissue-specific vectors for treatment of inherited diseases
Toscano, M. G., Romero, Z. G., Muñoz, P., Cobo, M., Benabdellah, K., & Martín, F. (2010) · Gene Therapy · doi:10.1038/gt.2010.138 · Cited by 48
Samardzija, M., Tanimoto, N., Kostic, C., Beck, S. C., Oberhauser, V., Joly, S., Thiersch, M., Fahl, E., Arsenijévic, Y., Lintig, J. V., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp026 · Cited by 48
Gruntman, A. M., Su, L., Su, Q., Gao, G., Mueller, C., & Flotte, T. R. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.040 · Cited by 48
Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy
Gorovits, B., Azadeh, M., Buchlis, G., Fiscella, M., Harrison, T., Havert, M., Janetzki, S., Jawa, V., Long, B. R., Mahnke, Y. D., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00814-5 · Cited by 49
de Lima, S., Habboub, G., & Benowitz, L. I. (2012) · International review of neurobiology · doi:10.1016/b978-0-12-407178-0.00007-7 · Cited by 47
Chen, F. K., Patel, P. J., Webster, A. R., Coffey, P. J., Tufail, A., & da Cruz, L. (2010) · Retina · doi:10.1097/iae.0b013e3181e46af3 · Cited by 47
Crossland, M. D., Luong, V., Rubin, G. S., & Fitzke, F. W. (2011) · BMC Ophthalmology · doi:10.1186/1471-2415-11-5 · Cited by 47
Self-citationBogner, B., Boye, S. L., Min, S.-H., Peterson, J. J., Ruan, Q., Zhang, Z., Reitsamer, H. A., Hauswirth, W. W., & Boye, S. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128759 · Cited by 47
Gene and Induced Pluripotent Stem Cell Therapy for Retinal Diseases
Maeda, A., Mandai, M., & Takahashi, M. (2019) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083118-015043 · Cited by 52
Investigation and Restoration of BEST1 Activity in Patient-derived RPEs with Dominant Mutations
Ji, C., Li, Y., Kittredge, A., Hopiavuori, A. R., Ward, N., Yao, P., Fukuda, Y., Zhang, Y., Tsang, S. H., & Yang, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-54892-7 · Cited by 47
Iron metabolism in the eye: A review
Goralska, M., Ferrell, J., Harned, J., Lall, M. M., Nagar, S., Fleisher, L. N., & McGahan, M. C. (2008) · Experimental Eye Research · doi:10.1016/j.exer.2008.10.026 · Cited by 49
Vincent, A., Wright, T., Garcia-Sanchez, Y., Kisilak, M. L., Campbell, M. C. W., Westall, C. A., & Héon, E. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-10971 · Cited by 47
The use of canine models of inherited retinal degeneration to test novel therapeutic approaches
Beltran, W. A. (2009) · Veterinary Ophthalmology · doi:10.1111/j.1463-5224.2009.00694.x · Cited by 47
Hippert, C., Ibanes, S., Serratrice, N., Court, F., Malecaze, F., Kremer, E. J., & Kalatzis, V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035318 · Cited by 47
Evaluation of AAV-DJ vector for retinal gene therapy
Katada, Y., Kobayashi, K., Tsubota, K., & Kurihara, T. (2019) · PeerJ · doi:10.7717/peerj.6317 · Cited by 46
Manfredsson, F. P., Okun, M. S., & Mandel, R. J. (2009) · Current Gene Therapy · doi:10.2174/156652309789753400 · Cited by 46
Ku, C. A., Chiodo, V. A., Boye, S. L., Goldberg, A. F. X., Li, T., Hauswirth, W. W., & Ramamurthy, V. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr391 · Cited by 47
Gene Therapy of Inherited Retinal Degenerations: Prospects and Challenges
Trapani, I., Banfi, S., Simonelli, F., Surace, E. M., & Auricchio, A. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.030 · Cited by 46
Centronuclear myopathies under attack: A plethora of therapeutic targets
Tasfaout, H., Cowling, B. S., & Laporte, J. (2018) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-180309 · Cited by 51
Dan, H., Huang, X., Xing, Y., & Shen, Y. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1131 · Cited by 46
Dual and triple AAV delivery of large therapeutic gene sequences into the inner ear
Akil, O. (2020) · Hearing Research · doi:10.1016/j.heares.2020.107912 · Cited by 47
Clinical and Rehabilitative Management of Retinitis Pigmentosa:Up-to-Date
Nadai, K. D., Romano, M., Binotto, A., Costagliola, C., Sato, G., & Parmeggiani, F. (2011) · Current Genomics · doi:10.2174/138920211795860125 · Cited by 46
Li, W., Kong, F., Li, X., Dai, X., Liu, X., Zheng, Q., Wu, R., Zhou, X., Lü, F., Chang, B., et al. (2009) · PubMed · Cited by 45
Gene delivery to the retina: focus on non-viral approaches
Naik, R. J., Mukhopadhyay, A., & Ganguli, M. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.09.012 · Cited by 47
Cao, H., Machuca, T., Yeung, J. C., Wu, J., Du, K., Duan, C., Hashimoto, K., S, V. L., Coates, A. L., Leung, K., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.55 · Cited by 45
Progress in Gene Therapy for Prostate Cancer
Ahmed, K. A., Davis, B. J., Wilson, T. M., Wiseman, G. A., Federspiel, M. J., & Morris, J. C. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00172 · Cited by 45
Contreras‐Ruiz, L., Zorzi, G. K., Hileeto, D., López‐García, A., Calonge, M., Seijo, B., Sánchez, A., & Diebold, Y. (2012) · Gene Therapy · doi:10.1038/gt.2012.56 · Cited by 45
Tam, L. C. S., Kiang, A., Campbell, M., Keaney, J., Farrar, G. J., Humphries, M. M., Kenna, P. F., & Humphries, P. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq369 · Cited by 45
Tolmachova, T., Tolmachov, O. E., Wavre‐Shapton, S. T., Tracey‐White, D., Futter, C. E., & Seabra, M. C. (2012) · The Journal of Gene Medicine · doi:10.1002/jgm.1652 · Cited by 45
Optimized Technique for Subretinal Injections in Mice
Mühlfriedel, R. L., Michalakis, S., Garrido, M. G., Biel, M., & Seeliger, M. W. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-080-9_24 · Cited by 45
Ashtari, M., Nikonova, E. S., Marshall, K. A., Young, G. J., Aravand, P., Pan, W., Ying, G., Willett, A. E., Mahmoudian, M., Maguire, A. M., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.01.029 · Cited by 45
Askou, A. L., Alsing, S., Holmgaard, A., Bek, T., & Corydon, T. J. (2017) · Acta Ophthalmologica · doi:10.1111/aos.13407 · Cited by 46
Jacobson, S. G., Cideciyan, A. V., Ho, A. C., Peshenko, I. V., Garafalo, A. V., Román, A. J., Sumaroka, A., Wu, V. F., Krishnan, A. K., Sheplock, R., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102409 · Cited by 45
Lai, C., Estcourt, M. J., Wikström, M. E., Himbeck, R. P., Barnett, N. L., Brankov, M., Tee, L. B. G., Dunlop, S. A., Degli‐Esposti, M. A., & Rakoczy, E. P. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-3253 · Cited by 46
Dev Borman, A., Ocaka, L. A., Mackay, D. S., Ripamonti, C., Henderson, R. H., Moradi, P., Hall, G., Black, G. C., Robson, A. G., Holder, G. E., et al. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-9548 · Cited by 44
Self-citationRetinal Structure in RPE65-Associated Retinal Dystrophy
Kumaran, N., Georgiou, M., Bainbridge, J. W. B., Bertelsen, M., Larsen, M., Blanco-Kelly, F., Ayuso, C., Tran, H. V., Munier, F. L., Kalitzeos, A., et al. (2020) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.61.4.47 · Cited by 44
Self-citationGene therapy for Leber congenital amaurosis: advances and future directions
Hufnagel, R. B., Ahmed, Z. M., Corrêa, Z. M., & Sisk, R. A. (2012) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-012-2028-2 · Cited by 46
Spampanato, C., Leonibus, E. D., Dama, P., Gargiulo, A., Fraldi, A., Sorrentino, N. C., Russo, F., Nusco, E., Auricchio, A., Surace, E. M., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.299 · Cited by 47
Testa, F., Surace, E. M., Rossi, S., Marrocco, E., Gargiulo, A., Iorio, V. D., Ziviello, C., Nesti, A., Fecarotta, S., Bacci, M. L., et al. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6543 · Cited by 44
Contemporary Animal Models For Human Gene Therapy Applications
Gopinath, C., Nathar, T. J., Ghosh, A., Hickstein, D. D., & Nelson, E. J. R. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150929110424 · Cited by 44
Kondkar, A. A., & Abu‐Amero, K. K. (2019) · Experimental Eye Research · doi:10.1016/j.exer.2019.107834 · Cited by 44
PEG–PLA microparticles for encapsulation and delivery of Tat-EGFP to retinal cells
Rafat, M., Cléroux, C. A., Fong, W. G., Baker, A. N., Leonard, B. C., O’Connor, M. D., & Tsilfidis, C. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.01.031 · Cited by 44
AAV for pain: steps towards clinical translation
Beutler, A. S., & Reinhardt, M. (2009) · Gene Therapy · doi:10.1038/gt.2009.23 · Cited by 44
Evaluation of 9- cis -Retinyl Acetate Therapy in Rpe65 −/− Mice
Maeda, T., Maeda, A., Casadesús, G., Palczewski, K., & Margaron, P. (2009) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-3700 · Cited by 44
Barriers for retinal gene therapy: separating fact from fiction.
Kumar-Singh, R. (2008) · Vision Research · doi:10.1016/j.visres.2008.05.005 · Cited by 43
Sodi, A., Banfi, S., Testa, F., Corte, M. D., Passerini, I., Pelo, E., Rossi, S., Simonelli, F., & Italian IRD Working Group (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01868-4 · Cited by 44
Allocca, M., Manfredi, A., Iodice, C., Vicino, U. D., & Auricchio, A. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-6269 · Cited by 43
Combined Rod and Cone Transduction by Adeno-Associated Virus 2/8
Manfredi, A., Marrocco, E., Puppo, A., Cesi, G., Sommella, A., Corte, M. D., Rossi, S., Giunti, M., Craft, C. M., Bacci, M. L., et al. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.154 · Cited by 43
Novel Viral Vector Systems for Gene Therapy
Stone, D. (2010) · Viruses · doi:10.3390/v2041002 · Cited by 44
Massively parallel sequencing for early molecular diagnosis in Leber congenital amaurosis
Coppieters, F., Wilde, B. D., Lefever, S., Meester, E. D., Rocker, N. D., Cauwenbergh, C. V., Pattyn, F., Meire, F. M., Leroy, B. P., Hellemans, J., et al. (2012) · Genetics in Medicine · doi:10.1038/gim.2011.51 · Cited by 43
Gene Therapy for MERTK-Associated Retinal Degenerations
LaVail, M. M., Yasumura, D., Matthes, M. T., Yang, H., Hauswirth, W. W., Deng, W., & Vollrath, D. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17121-0_65 · Cited by 43
Genetic manipulation for inherited neurodegenerative diseases: myth or reality?
Yu‐Wai‐Man, P. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308329 · Cited by 43
AAV-CRISPR/Cas9–Mediated Depletion of VEGFR2 Blocks Angiogenesis In Vitro
Wu, W., Duan, Y., Ma, G., Zhou, G., Park‐Windhol, C., D'Amore, P. A., & Lei, H. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-21902 · Cited by 43
Personalised genome editing – The future for corneal dystrophies
Moore, T., Christie, K. A., Marshall, J., & Nesbit, M. A. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.01.004 · Cited by 44
Translating CRISPR-Cas Therapeutics: Approaches and Challenges
Tay, L. S., Palmer, N. D., Panwala, R., Chew, W. L., & Mali, P. (2020) · The CRISPR Journal · doi:10.1089/crispr.2020.0025 · Cited by 43
Stingl, K. T., Kempf, M., Bartz‐Schmidt, K. U., Dimopoulos, S., Reichel, F. F., Jung, R., Kelbsch, C., Kohl, S., Kortüm, F. C., Nasser, F., et al. (2021) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-318286 · Cited by 43
Bouaita, A., Augustin, S., Lechauve, C., Cwerman‐Thibault, H., Bénit, P., Simonutti, M., Pâques, M., Rustin, P., Sahel, J., & Corral‐Debrinski, M. (2011) · Brain · doi:10.1093/brain/awr290 · Cited by 43
Retinal Gene Therapy Coming of Age
Cepko, C. L., & Vandenberghe, L. H. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.050 · Cited by 43
Success in sight: The eyes have it! Ocular gene therapy trials for LCA look promising
Bainbridge, J. W., & Ali, R. R. (2008) · Gene Therapy · doi:10.1038/gt.2008.117 · Cited by 43
Self-citationVillate-Beitia, I., Gallego, I., Martínez-Navarrete, G., Zárate, J., López-Méndez, T., Soto-Sánchez, C., Santos-Vizcaíno, E., Puras, G., Fernández, E., & Pedraz, J. L. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.07.035 · Cited by 42
Systemic low‐molecular weight drug delivery to pre‐selected neuronal regions
Campbell, M., Humphries, M. M., Kiang, A., Nguyen, A. T. H., Gobbo, O. L., Tam, L. C. S., Suzuki, M., Hanrahan, F., Ozaki, E., Farrar, G. ‐., et al. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100126 · Cited by 42
McGuigan, D. B., Román, A. J., Cideciyan, A. V., Matsui, R., Gruzensky, M. L., Sheplock, R., & Jacobson, S. G. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19302 · Cited by 42
Use of Virtual Reality Simulation to Identify Vision-Related Disability in Patients With Glaucoma
Lam, A. K. N., To, E., Weinreb, R. N., Yu, M., Mak, H. K., Lai, G. W. K., Chiu, V. S. M., Wu, K., Zhang, X. J., Cheng, T. P. H., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.0392 · Cited by 42
Glycosidic enzymes enhance retinal transduction following intravitreal delivery of AAV2.
Cehajic‐Kapetanovic, J., Goff, M. L., Allen, A. E., Lucas, R. J., & Bishop, P. N. (2011) · PubMed Central · Cited by 42
Gene therapy and transplantation in the retinofugal pathway
Harvey, A. R., Hellström, M., & Rodger, J. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17510-6 · Cited by 42
Gene Therapy Targeting Glaucoma: Where Are We?
Liu, X., Rasmussen, C. A., Gabelt, B. T., Brandt, C. R., & Kaufman, P. L. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.04.003 · Cited by 42
Rodger, J., Drummond, E., Hellström, M., Robertson, D., & Harvey, A. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031061 · Cited by 42
Choroideremia: Towards a Therapy
Kalatzis, V., Hamel, C., & MacDonald, I. M. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.009 · Cited by 42
Metadata
- Authors
- Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., Petersen-Jones, S., Bhattacharya, S. S., Thrasher, A. J., Fitzke, F. W., Carter, B. J., Rubin, G. S., Moore, A. T., & Ali, R. R.
- Affiliations
- Moorfields Eye Hospital (GB)
- University College London (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-05-22
- Volume
- 358
- Issue
- 21
- Pages
- 2231-2239
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2151809142
- Cited by
- 1,924
- References
- 25
- Citations by year
- 2026: 22 · 2025: 43 · 2024: 47 · 2023: 57 · 2022: 61 · 2021: 94 · 2020: 97 · 2019: 83 · 2018: 101 · 2017: 115 · 2016: 98 · 2015: 155 · 2014: 142 · 2013: 149 · 2012: 151
- FWCI
- 69.45
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- Leber congenital amaurosis, RPE65, gene therapy, subretinal injection, retinal dystrophy, visual function, microperimetry, visual acuity, electroretinogram
- MeSH terms
- Retinoid Isomerohydrolase, Dependovirus, Adolescent, Adult, Blindness, Carrier Proteins, Eye Proteins, Genetic Vectors, Humans, Injections, Mutation, Retina, Retinal Degeneration, Visual Acuity, Genetic Therapy, Gene Transfer Techniques, DNA, Complementary, cis-trans-Isomerases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
